{"entity":{"id":"lcb02a","kind":"drug","name":"LCB02A","aka":[],"tldr":"LCB02A is an experimental monoclonal antibody from LigaChem Biosciences in phase 2 trials, aimed at Claudin 18.2.","summary":"LCB02A is a monoclonal antibody developed by LigaChem Biosciences. Its target is Claudin 18.2. ClinicalTrials.gov describes the intervention as: CLDN18.2-directed human monoclonal antibody (Ab) linked to a topoisomerase I inhibiting payload. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07460375, plans to enrol 191 participants with primary completion expected 2030-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of LCB02A","url":"https://clinicaltrials.gov/search?intr=LCB02A"},{"label":"Sponsor page","url":"https://www.ligachembio.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["cldn18-2"],"drugs":[],"companies":["ligachem-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07460375"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"Monoclonal antibody directed at Claudin 18.2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lcb02a/","neighbours":{"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"ligachem-biosciences","kind":"company","name":"LigaChem Biosciences","route":"/companies/ligachem-biosciences/"}],"trial":[{"id":"nct07460375","kind":"trial","name":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","route":"/trials/nct07460375/"}]}}